Answer
Systemic hypersensitivity reactions reported with pegvisomant after marketing include anaphylactic/anaphylactoid reactions, laryngospasm, angioedema and generalized skin reactions (rash, erythema, pruritus and urticaria), with some patients requiring hospitalization.
Sources for this answer
- SOMAVERT 10mg powder and solvent for solution for injectionPfizer Limited · emc · SmPC §4.8 Undesirable effects · Version 26Document updated
Sources checked